ER Positive Breast Cancer Clinical Trials
1 recruiting
Showing 1–7 of 7 trials
Recruiting
Phase 3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerER Positive Breast Cancer+1 more
Olema Pharmaceuticals, Inc.1,000 enrolled35 locationsNCT07085767
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 2
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Breast CancerER Positive Breast CancerHER2-positive Breast Cancer+1 more
Ruth O'Regan30 enrolled4 locationsNCT04886531
Recruiting
Phase 2
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Breast CancerBreast Cancer FemaleHER2-negative Breast Cancer+2 more
Sarah Sammons, MD58 enrolled3 locationsNCT06176261
Recruiting
Role of the Immune Environment in Response to Therapy in Breast Cancer
Breast CancerHER2-negative Breast CancerER Positive Breast Cancer+1 more
Abramson Cancer Center at Penn Medicine300 enrolled1 locationNCT05396612
Recruiting
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
Metastatic Breast CancerHER2-negative Breast CancerER Positive Breast Cancer
Fondazione Sandro Pitigliani150 enrolled1 locationNCT04660435
Recruiting
Phase 2
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
Metastatic Breast CancerER Positive Breast CancerPremenopausal Breast Cancer
National Taiwan University Hospital42 enrolled1 locationNCT05720260